Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Solid Tumor, Adult 1Pyloric Stenosis, Hypertrophic 1Nasopharyngeal Carcinoma 1Lymphoproliferative Disorders 1Epstein-Barr Virus Infections 1EBV Lymphomas 1Advanced Cancer 1

Interventions

pembrolizumab 4Cisplatin 4nedaplatin 2Heavy Ion Radiotherapy 2Gemcitabine 2donafenib 1apatinib 1Varenicline 1Valganciclovir 1Therapeutics 1Tegafur 1S 1 (combination) 1Platinum 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Nicotine Replacement Therapy 1Mitomycin 1Ifosfamide 1Fluorouracil 1Eucalyptus Oil 1Epirubicin 1Doxorubicin 1Coal Tar 1Chemotherapy, Adjuvant 1Cetuximab 1Carboplatin 1Bupropion 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Nasopharyngeal Carcinoma × Valganciclovir × Clear all
NCT05166577 2025-03-12

Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC

Viracta Therapeutics, Inc.

Phase 1 Terminated
26 enrolled 23 charts
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡